MERCK Kommanditgesellschaft auf Aktien (MKGAF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:57PM EDT
| Previous close | 162.53 |
| Open | 173.85 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 173.22 - 176.52 |
| 52-week range | 162.20 - 264.40 |
| Volume | |
| Avg. volume | 233 |
| Market cap | 77.594B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 23.05 |
| EPS (TTM) | 7.66 |
| Earnings date | N/A |
| Forward dividend & yield | 1.97 (1.20%) |
| Ex-dividend date | 25 Apr 2022 |
| 1y target est | N/A |
- GlobeNewswire
Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer
New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.Avelumab (BAVENCIO®) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or gastroesophageal junction adenocarcinomas (neoHERIZON)neoHERIZON will assess HER-Vaxx in combination with chemotherapy with or without avelumab in HER-2 positive gastric cancer SYDNEY, Australia., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial supply agreement with M
- Zacks
Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
© 2022 Yahoo. All rights reserved.
